General Information of Drug (ID: DM0LGTY)

Drug Name
PMID27998201-Compound-6 Drug Info
Cross-matching ID
TTD Drug ID
DM0LGTY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Cathepsin L (CTSL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KGP94 DM2NZ6K Coagulation defect 3B10.0 Clinical trial [2]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [1]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [3]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [1]
PMID27998201-Compound-7 DMU4QYR Abdominal aortic aneurysm BD50.4 Patented [1]
PMID27998201-Compound-1 DM5QH4C Coronavirus infection 1D92 Patented [1]
PMID27998201-Compound-19 DM67RMX Solid tumour/cancer 2A00-2F9Z Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin S (CTSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7625 DMDGPKS Autoimmune disease 4A40-4A45 Phase 2 [4]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [5]
VBY- 891 DMTKPH4 Autoimmune diabetes 5A10 Phase 1 [6]
VBY- 036 DMULRYC Neuropathic pain 8E43.0 Phase 1 [7]
VBY-129 DM4YIWK Autoimmune diabetes 5A10 Phase 1 [8]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [1]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [3]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [1]
Cathepsin S (CTSS) TTUMQVO CATS_HUMAN Inhibitor [1]

References

1 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
2 Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
3 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
7 Clinical pipeline report, company report or official report of ViroBay.
8 Clinical pipeline report, company report or official report of ViroBay.